31.23
price up icon2.43%   +0.74
after-market  After Hours:  31.23 
loading
Perrigo Company plc stock is currently priced at $31.23, with a 24-hour trading volume of 943.27K. It has seen a +2.43% increased in the last 24 hours and a -0.29% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $30.39 pivot point. If it approaches the $31.43 resistance level, significant changes may occur.
Previous Close:
$30.49
Open:
$30.48
24h Volume:
943.27K
Market Cap:
$4.23B
Revenue:
$4.66B
Net Income/Loss:
$-12.70M
P/E Ratio:
-62.46
EPS:
-0.5
Net Cash Flow:
$303.80M
1W Performance:
+3.96%
1M Performance:
-0.29%
6M Performance:
+6.66%
1Y Performance:
-13.47%
1D Range:
Value
$30.24
$31.29
52W Range:
Value
$25.77
$40.28

Perrigo Company plc Stock (PRGO) Company Profile

Name
Name
Perrigo Company plc
Name
Phone
353 1 709 4000
Name
Address
Treasury Building, Lower Grand Canal Street, Dublin
Name
Employee
10,400
Name
Twitter
@perrigocompany
Name
Next Earnings Date
2024-05-07
Name
Latest SEC Filings
Name
PRGO's Discussions on Twitter

Perrigo Company plc Stock (PRGO) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-17-23 Initiated Piper Sandler Overweight
Mar-07-23 Initiated Canaccord Genuity Buy
Sep-14-22 Upgrade Argus Hold → Buy
Sep-06-22 Upgrade Wells Fargo Equal Weight → Overweight
Oct-14-21 Upgrade Raymond James Mkt Perform → Outperform
Sep-30-21 Upgrade Jefferies Hold → Buy
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Jan-06-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Apr-17-20 Downgrade Argus Buy → Hold
Mar-24-20 Upgrade JP Morgan Neutral → Overweight
Mar-20-20 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-18-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Oct-11-19 Upgrade Argus Hold → Buy
Mar-20-19 Initiated SunTrust Hold
Nov-13-18 Downgrade Berenberg Buy → Hold
Aug-10-18 Reiterated Stifel Hold
Jul-30-18 Downgrade Argus Buy → Hold
Jul-12-18 Downgrade Goldman Neutral → Sell
Jan-03-18 Initiated Leerink Partners Mkt Perform
Dec-08-17 Upgrade Argus Hold → Buy
Nov-10-17 Upgrade RBC Capital Mkts Underperform → Sector Perform
Oct-05-17 Reiterated UBS Buy
Sep-07-17 Initiated Oppenheimer Outperform
Aug-11-17 Upgrade Goldman Sell → Neutral
Aug-11-17 Reiterated RBC Capital Mkts Underperform
Jun-16-17 Initiated Cantor Fitzgerald Overweight
Jun-05-17 Downgrade RBC Capital Mkts Sector Perform → Underperform
Mar-03-17 Reiterated B. Riley & Co. Neutral
View All

Perrigo Company plc Stock (PRGO) Financials Data

Perrigo Company plc (PRGO) Revenue 2024

PRGO reported a revenue (TTM) of $4.66 billion for the quarter ending December 31, 2023, a +4.58% rise year-over-year.
loading

Perrigo Company plc (PRGO) Net Income 2024

PRGO net income (TTM) was -$12.70 million for the quarter ending December 31, 2023, a +90.97% increase year-over-year.
loading

Perrigo Company plc (PRGO) Cash Flow 2024

PRGO recorded a free cash flow (TTM) of $303.80 million for the quarter ending December 31, 2023, a +44.05% increase year-over-year.
loading

Perrigo Company plc (PRGO) Earnings per Share 2024

PRGO earnings per share (TTM) was -$0.10 for the quarter ending December 31, 2023, a +90.38% growth year-over-year.
loading
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc has a collaborative agreement with the Sol-Gel Technologies Ltd. for the development, manufacturing, and commercialization of an ivermectin cream in the United States. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
$13.31
price down icon 1.11%
$73.12
price down icon 1.20%
$55.95
price down icon 0.14%
drug_manufacturers_specialty_generic RDY
$70.92
price down icon 0.80%
$11.55
price up icon 1.67%
$138.97
price down icon 0.80%
Cap:     |  Volume (24h):